Bristol Myers will focus on bolt-on M&A after Karuna acquisition

Bristol Myers Squibb likely won’t be on the hunt for big M&A targets in 2024 after pulling off a $14 billion deal for Karuna Therapeutics and its schizophrenia drug, executives said during Friday’s earnings call.

This year’s M&A strategy will focus more on bolt-ons and licensing opportunities instead, as new…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks